Mirati Therapeutics, Inc. (MRTX) Upgraded to “Sell” at ValuEngine
Mirati Therapeutics, Inc. (NASDAQ:MRTX) was upgraded by equities researchers at ValuEngine from a “strong sell” rating to a “sell” rating in a note issued to investors on Friday.
Several other equities analysts also recently weighed in on the stock. Leerink Swann lifted their target price on shares of Mirati Therapeutics from $7.00 to $9.00 and gave the stock a “market perform” rating in a research note on Friday. Jefferies Group LLC reiterated a “hold” rating and issued a $4.50 target price on shares of Mirati Therapeutics in a research note on Monday, June 12th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and two have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $8.15.
Mirati Therapeutics (MRTX) traded up 135.79% during mid-day trading on Friday, reaching $11.20. 48,767,398 shares of the company’s stock were exchanged. The company has a 50-day moving average of $5.21 and a 200-day moving average of $4.48. Mirati Therapeutics has a 52-week low of $2.70 and a 52-week high of $12.40. The stock’s market cap is $279.65 million.
COPYRIGHT VIOLATION WARNING: “Mirati Therapeutics, Inc. (MRTX) Upgraded to “Sell” at ValuEngine” was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another site, it was copied illegally and reposted in violation of United States & international trademark and copyright law. The correct version of this article can be read at https://www.americanbankingnews.com/2017/09/15/mirati-therapeutics-inc-mrtx-upgraded-to-sell-at-valuengine.html.
Several institutional investors and hedge funds have recently bought and sold shares of the company. Broadfin Capital LLC increased its stake in shares of Mirati Therapeutics by 19.1% in the second quarter. Broadfin Capital LLC now owns 2,490,801 shares of the biotechnology company’s stock worth $9,091,000 after purchasing an additional 400,000 shares in the last quarter. Susquehanna International Group LLP increased its stake in shares of Mirati Therapeutics by 46.5% in the second quarter. Susquehanna International Group LLP now owns 50,509 shares of the biotechnology company’s stock worth $184,000 after purchasing an additional 16,030 shares in the last quarter. Goldman Sachs Group Inc. increased its stake in shares of Mirati Therapeutics by 845.4% in the second quarter. Goldman Sachs Group Inc. now owns 98,251 shares of the biotechnology company’s stock worth $359,000 after purchasing an additional 87,858 shares in the last quarter. PDT Partners LLC purchased a new position in shares of Mirati Therapeutics in the second quarter worth about $200,000. Finally, Dimensional Fund Advisors LP grew its stake in Mirati Therapeutics by 53.3% during the second quarter. Dimensional Fund Advisors LP now owns 199,563 shares of the biotechnology company’s stock valued at $728,000 after acquiring an additional 69,377 shares in the last quarter. Hedge funds and other institutional investors own 60.17% of the company’s stock.
Mirati Therapeutics Company Profile
Mirati Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of oncology products. The companys clinical stage product candidates include glesatinib, an orally-bioavailable, potent, small molecule kinase inhibitor that is in Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC) patients with genetic alterations of MET; and in Phase Ib clinical trials in patients with genetic alterations of MET and Axl in NSCLC and other solid tumors.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Mirati Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.